Holen Sie sich die Stockscreener-App
1.74
1.75%
0.03
Handel nachbörslich:
1.72
-0.02
-1.15%
Schlusskurs vom Vortag:
$1.71
Offen:
$1.76
24-Stunden-Volumen:
2.68M
Relative Volume:
0.78
Marktkapitalisierung:
$490.66M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-225.14M
KGV:
-0.8878
EPS:
-1.96
Netto-Cashflow:
$-192.27M
1W Leistung:
+2.35%
1M Leistung:
+1.75%
6M Leistung:
+52.63%
1J Leistung:
+64.15%
1-Tages-Spanne:
$1.61
$1.785
1-Wochen-Bereich:
$1.58
$1.785
52-Wochen-Spanne:
$0.46
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
Firmenname
Invivyd Inc
Sektor
Branche
Telefon
(781) 819-0080
Adresse
209 CHURCH STREET, NEW HAVEN
Compare IVVD vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
1.74 | 482.20M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-22 | Eingeleitet | BTIG Research | Buy |
| 2025-11-25 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2025-10-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-04-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-26 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Invivyd Inc Aktie (IVVD) Neueste Nachrichten
Invivyd Names Michael Mina Chief Medical Officer - Contract Pharma
Invivyd, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Invivyd Appoints Michael Mina, M.D., Ph.D. as Chief Medical Officer - citybiz
Invivyd (IVVD) Q4 2025 Earnings Call Transcript - AOL.com
Invivyd Q4 2025 slides: revenue surges 31%, pipeline advances By Investing.com - Investing.com India
Earnings call transcript: Invivyd Q4 2025 shows robust growth and strategic expansion - Investing.com India
Invivyd appoints Michael Mina as chief medical officer - Investing.com India
Invivyd Advances VYD2311 With Key Phase 3 Alignments - TipRanks
Invivyd 2025 10-K: Revenue $53.4M, Net Loss $52.5M - TradingView
Michael Mina named chief medical officer, Invivyd, Inc. announces - Traders Union
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates - The Manila Times
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer - The Manila Times
Invivyd's Fourth Quarter 2025: Market Achievements Reflected in Valuation, Uneven Pipeline Risk - Bitget
An Overview of Invivyd's Earnings - Benzinga
Invivyd (IVVD) to Release Earnings on Thursday - MarketBeat
Invivyd Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Invivyd (IVVD): Post-Data Plunge, Cash Runway And Next Catalysts For US Traders - AD HOC NEWS
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
IVVD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026 - The Manila Times
New Invivyd staff get options on 192,000 shares at $1.69 each - Stock Titan
Invivyd (NASDAQ:IVVD) Earns "Buy" Rating from BTIG Research - MarketBeat
New study maps COVID protection to antibody levels, not variants - Stock Titan
Aug Breakouts: Is Eaton Vance Senior Income Trust gaining market share2025 Bull vs Bear & Real-Time Price Movement Reports - baoquankhu1.vn
Lobbying Update: $20,000 of INVIVYD INC. lobbying was just disclosed - Quiver Quantitative
Invivyd (IVVD) CHRO Green sells $63k in stock after option exercise - Investing.com India
Invivyd CSO Allen sells shares worth $58,600 - Investing.com India
Invivyd CSO Allen sells shares worth $58,600 By Investing.com - Investing.com Nigeria
Invivyd (IVVD) CFO Duke sells shares worth $63,350 - Investing.com Australia
Invivyd (NASDAQ: IVVD) legal chief sells shares in tax sell-to-cover plan - Stock Titan
Invivyd (IVVD) HR chief logs RSU vesting and tax sell-to-cover sales - Stock Titan
Timothy Edward Lee Sells 19,663 Shares of Invivyd (NASDAQ:IVVD) Stock - MarketBeat
RA Capital discloses 9.99% Invivyd (IVVD) stake via shares and warrants - Stock Titan
BVF group discloses 9% Invivyd (IVVD) stake via shares and warrants - Stock Titan
Invivyd’s COVID antibody VYD2311 receives FDA fast track - MSN
Point72 discloses 6% Invivyd (IVVD) ownership in Schedule 13G/A - Stock Titan
Can Invivyd Inc. navigate macro headwindsMarket Performance Recap & Safe Capital Investment Plans - mfd.ru
Does Invivyd Inc. have a sustainable dividendEarnings Overview Summary & Safe Capital Preservation Plans - mfd.ru
What makes Invivyd Inc. stock attractive to growth funds2025 Retail Activity & Daily Profit Maximizing Trade Tips - mfd.ru
Invivyd, Inc. (NASDAQ:IVVD) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Invivyd prices $125M stock offering at $2.50 per share - MSN
Analysts Offer Insights on Healthcare Companies: Invivyd (IVVD) and Pfizer (PFE) - The Globe and Mail
H.C. Wainwright reiterates Buy rating on Invivyd stock amid FDA feedback - Investing.com Nigeria
Invivyd receives FDA feedback on COVID antibody vs mRNA vaccine trial - Investing.com Nigeria
Invivyd receives FDA feedback on COVID antibody vs mRNA vaccine trial By Investing.com - Investing.com South Africa
Invivyd rises as FDA agrees with late-stage trial design for COVID-19 therapy - Seeking Alpha
Invivyd aligns with FDA for Phase 3 vaccine trial - Traders Union
Invivyd rises on late-stage trial testing COVID antibody against mRNA vaccines - TradingView
Finanzdaten der Invivyd Inc-Aktie (IVVD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Invivyd Inc-Aktie (IVVD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Allen Robert D. III | Chief Scientific Officer |
Feb 17 '26 |
Sale |
1.54 |
18,189 |
28,004 |
133,879 |
| Green Julie | Chief Human Resources Officer |
Feb 18 '26 |
Sale |
1.58 |
20,964 |
33,077 |
107,717 |
| Green Julie | Chief Human Resources Officer |
Feb 17 '26 |
Sale |
1.54 |
19,663 |
30,273 |
128,681 |
| Duke William E. | Chief Financial Officer |
Feb 18 '26 |
Sale |
1.58 |
20,964 |
33,077 |
107,717 |
| Duke William E. | Chief Financial Officer |
Feb 17 '26 |
Sale |
1.54 |
19,663 |
30,273 |
128,681 |
| Lee Timothy Edward | Chief Commercial Officer |
Feb 18 '26 |
Sale |
1.58 |
20,964 |
33,077 |
117,717 |
| Lee Timothy Edward | Chief Commercial Officer |
Feb 17 '26 |
Sale |
1.54 |
19,663 |
30,273 |
138,681 |
| Andersen Jill | Chief Legal Officer, Secretary |
Feb 18 '26 |
Sale |
1.58 |
34,939 |
55,127 |
181,736 |
| Andersen Jill | Chief Legal Officer, Secretary |
Feb 17 '26 |
Sale |
1.54 |
32,771 |
50,454 |
216,675 |
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):